

# Risk – Reward of Developing a Herceptin Biosimilar – A Thorough Assessment

<https://marketpublishers.com/r/RC862A0FE6FEN.html>

Date: October 2012

Pages: 70

Price: US\$ 2,000.00 (Single User License)

ID: RC862A0FE6FEN

## Abstracts

Herceptin exclusivity is expiring in major geographies and many Biosimilar players (both experienced and new entrant) are looking to have a share of this potential \$6billion pie. Herceptin sales are critical to Roche as it comprise about 15% of its cumulative Pharma sales. While eyeing for this potential lucrative opportunity, there are several risks and barriers that Biosimilar players should be aware. The report – “Risk – Reward of Developing a Herceptin biosimilar – A thorough assessment” looks into several aspects of potential opportunity size for Biosimilar players, with regard to:

European Experience of Biosimilars

Current market positioning of Herceptin across geography

Different technologies deployed by biosimilar players

Competition – Pipeline of Biosimilar and Biobetters targeting Herceptin

Potential Market Expansion post expiry of Market Exclusivity

Defense Strategies deployed by Roche

Ongoing Clinical trials and their impact on Market Opportunity

Global Regulatory Process and Hurdles

Risk/Reward profile of developing Herceptin biosimilar



## Contents

### **1. EXECUTIVE SUMMARY**

### **2. EUROPEAN EXPERIENCE OF BIOSIMILAR LAUNCH**

Pricing

Market share dynamics

### **3. INTRODUCTION HERCEPTIN**

Geography-wise Sales Forecast until patent expiry

Patent expiries in major geographies

Pricing in major geographies

Penetration in major emerging markets

Expected market expansion post patent expiry

Ongoing Clinical trials on Herceptin

### **4. ABOUT THE BIOSIMILAR SPACE**

Different technologies deployed by biosimilar players

Partnering deals in biosimilar

Cost of developing biosimilar/biobetter

Comparison USFDA and EUROPE biosimilar guideline

Requirement of Analytical methods

Interchangeability and substitution

Regulatory review process for biosimilar Principle and Concepts

Bridging Studies A way to reduce the launch timeline in multiple geographies

Importance of post-marketing safety in Non-ICH countries

A brief on biosimilar approval guidelines in geographies other than US and Europe

### **5. PIPELINE OF HERCEPTIN BIOSIMILAR AND BIOBETTERS**

Ongoing Clinical trials on Herceptin biosimilar/biobetter

A brief on companies developing Herceptin biosimilar

Financial capability

Technical capability

### **6. OPPORTUNITIES AND THREATS FOR HERCEPTIN BIOSIMILAR**

Defense strategy by Roche to woo away biosimilar threat in global markets and Emerging markets

Major clinical trials on Herceptin potential impact on its future sales

Physician's and Payers adaptation for using Biosimilar

Competitive threats Upcoming biobetters and novel biologics in HER2+ve Breast cancer and Gastric cancer

## **7. OUR VIEW ON RISK/REWARD PROFILE OF DEVELOPING HERCEPTIN BIOSIMILAR**

## I would like to order

Product name: Risk – Reward of Developing a Herceptin Biosimilar – A Thorough Assessment

Product link: <https://marketpublishers.com/r/RC862A0FE6FEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/RC862A0FE6FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970